Skip to main content

Plasma Detect Genome MRD - Baseline 

CPT

For CPT coding, call 800-222-7566, ext. 6-8400.

Test Details

Methodology

Tumor-informed whole genome sequencing utilizing matched FFPE tumor tissue, white blood cells and plasma obtained from peripheral whole blood

Nucleic acid extraction is performed and next-generation sequencing libraries are prepared for the tumor, germline and cell-free DNA, which are then sequenced. Data analysis is performed for alignment, quality control analyses, single nucleotide variant calling and filtering to provide the overall status for detectable ctDNA along with an estimate of tumor content. The analytical sensitivity of the Labcorp Plasma Detect Colon Genome MRD tests is 0.005% tumor content with 99.4% analytical specificity.

Use

The Labcorp Plasma Detect Genome MRD tests are intended for the detection of circulating tumor DNA (ctDNA) in stage III colon cancer patients after surgery or adjuvant chemotherapy to identify individuals who may have an increased risk of recurrence. Emerging evidence supports the clinical utility of detection of ctDNA in the diagnosis of disease progression, recurrence and/or relapse in advanced colorectal cancer. Patients with detectable ctDNA after surgery or adjuvant chemotherapy are at an increased risk of recurrence compared to patients without detectable ctDNA. ctDNA level (%) represents the proportion of the cell-free DNA sample that exhibits evidence of tumor-specific single nucleotide variants.

Special Instructions

This test currently is not approved for use in New York state.

If whole blood collected in a cell-free DNA BCT (Streck tube) and a formalin-fixed, paraffin-embedded tissue (FFPE) block or slides from tissue resection are not received together, forward the Streck tube to the testing laboratory by themselves. Do not hold the Streck tubes. A copy of the original pathology report, the date of the surgical resection and the test specific test requisition form are required for testing. If these are not received with the sample, testing will be delayed. Please direct any questions regarding this test to customer service at 800-345-4363. The testing location will begin the block procurement process; however, testing will be delayed. If the formalin-fixed resection is not received within 14 days, testing will be canceled.

Limitations

The analytical sensitivity of the Labcorp Plasma Detect Genome MRD tests may be limited by insufficient coverage in specific regions of the genome, inability to distinguish highly related human sequences and sequencing or other technical errors. The analysis of genetic alterations can also be hampered by multiple aspects related to the sample and DNA. Low quantity of DNA obtained can limit the amount of DNA molecules that can be successfully analyzed by next generation sequencing. 

The variant allele frequency and number of tumor-specific molecules depends on various factors including sample collection timing (post-surgery or while on therapy), pre-analytical sample processing and clinical characteristics unrelated to tumor status. The concentration of tumor-derived DNA can be a factor, as a portion of the DNA analyzed may be derived from contaminating normal cells. 

A negative result does not definitely indicate the absence of cancer. ctDNA dynamics may also reflect overall tumor burden response as a result of clinical intervention or during surveillance through longitudinal assessments. 

The Labcorp Plasma Detect Genome MRD tests are designed to detect ctDNA derived from the assayed tumor only and has not been validated to detect new primary tumors. 

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Specimen Requirements

Specimen

Whole blood collected in a cell-free DNA BCT (Streck tube) and formalin-fixed, paraffin-embedded tissue (FFPE) block or slides from tissue resection

Volume

20 mL whole blood collected in two cell-free DNA BCT (Streck tubes) and 9 pre-cut unstained slides from paraffin block cut at 5 micron thickness and 1 matching H&E reference slide or FFPE tissue block

Minimum Volume

10 mL whole blood collected in a cell-free DNA BCT (Streck tube); tumor surface area ≥ 4mm2 tumor area; tumor content ≥20% is preferred

Collection Instructions

Whole blood: Samples collected in cell-free DNA BCT are stable for up to seven days at temperatures between 2°C and 30°C. Indicate date and time of collection on test request form.

FFPE: Maintain blocks/slides at room temperature.

Causes for Rejection

Whole blood: Any tube type that is not cell-free DNA BCT (Streck tube)

FFPE: Specimen does not meet all of the above criteria for sample type, container, minimum volume, collection and storage; no tumor tissue in FFPE block or slides; broken or stained slides; fixative other than formalin

References

Alarcon CR, et al. Circulating tumour DNA ctDNA) in patients with stage III colon cancer: the multicentre prospective PROVENC3 study. British Journal of Surgery, in press.

Alarcon, CR, Georgiadis A, Franken IA, et al. Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treated with adjuvant chemotherapy: The PROVENC3 study. Cancer Res. 2024 Mar 15;84(6)Suppl:6559-6559.

Burbach JPM, Kurk SA, Coebergh van den Braak RRJ, et al. Prospective Dutch colorectal Cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. Acta Oncol. 2016 Nov;55(11):1273-1280. Epub 2016 Aug 25. PubMed 27560599

Henriksen TV, Tarazona N, Frydendahl A, et al. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. Clin Cancer Res. 2022 Feb 1;28(3):507-517. Epub 2021 Oct 8. PubMed 34625408

Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023 Jan;29(1):127-134. Epub 2023 Jan 16. PubMed 36646802

Schraa SJ, van Rooijen KL, van der Kruijssen DEW, et al. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. BMC Cancer. 2020 Aug 20;20(1):790. PubMed 32819390

Tie J, Cohen JD, Lahouel K, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022 Jun 16;386(24):2261-2272. Epub 2022 Jun 4. PubMed 35657320

Tie J, Cohen JD, Wang Y, et al. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncol. 2019 Dec 1;5(12):1710-1717. Erratum in: JAMA Oncol. 2019 Dec 1;5(12):1811. PubMed 31621801

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
484442 PlasmaDetectGenome MRD-Base REQUEST 484475 Tumor Status Pending
484442 PlasmaDetectGenome MRD-Base REQUEST 484476 Plasma Stabilization 8251-1
Order Code484442
Order Code NamePlasmaDetectGenome MRD-Base
Order LoincREQUEST
Result Code484475
Result Code NameTumor Status
UofM
Result LOINCPending
Order Code484442
Order Code NamePlasmaDetectGenome MRD-Base
Order LoincREQUEST
Result Code484476
Result Code NamePlasma Stabilization
UofM
Result LOINC8251-1
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 484443 ctDNA status Pending
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code484443
Result NamectDNA status
UofM
Result LOINCPending
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 484445 %ctDNA Pending
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code484445
Result Name%ctDNA
UofM
Result LOINCPending
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 484446 Indication Pending
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code484446
Result NameIndication
UofM
Result LOINCPending
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 484447 Location Pending
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code484447
Result NameLocation
UofM
Result LOINCPending
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 484591 Specimen Type 66746-9
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code484591
Result NameSpecimen Type
UofM
Result LOINC66746-9
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 484449 Specimen Type Pending
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code484449
Result NameSpecimen Type
UofM
Result LOINCPending
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 484452 Block ID Pending
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code484452
Result NameBlock ID
UofM
Result LOINCPending
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 484453 Background Pending
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code484453
Result NameBackground
UofM
Result LOINCPending
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 484454 Method Pending
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code484454
Result NameMethod
UofM
Result LOINCPending
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 484455 References Pending
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code484455
Result NameReferences
UofM
Result LOINCPending
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 484456 Director Review Pending
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code484456
Result NameDirector Review
UofM
Result LOINCPending
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 000000 Serial Monitoring N/A
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code000000
Result NameSerial Monitoring
UofM
Result LOINCN/A
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 480903 Microdissection Performed 8100-0
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code480903
Result NameMicrodissection Performed
UofM
Result LOINC8100-0
Reflex Table for Tumor Status
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484478 Plasma Detect - Landmark 511958 PDF 80563-0
Reflex 1
Order Code484478
Order NamePlasma Detect - Landmark
Result Code511958
Result NamePDF
UofM
Result LOINC80563-0